阿奇霉素序贯联合双黄连口服液治疗小儿支原体肺炎的效果观察

Observation on the effect of azithromycin sequential therapy combined with Shuanghuanglian oral liquid in the treatment of mycoplasma pneumonia in children

目的评价阿奇霉素序贯联合双黄连口服液治疗小儿支原体肺炎的临床效果。方法112例小儿支原体肺炎患儿,按照随机数字表法分为对照组和观察组,各56例。对照组采用阿奇霉素序贯治疗,观察组采用阿奇霉素序贯联合双黄连口服液治疗。比较两组治疗效果、不良反应发生情况及治疗前后炎症因子指标。结果观察组治疗总有效率为96.43%,显著高于对照组的64.29%,差异有统计学意义(P<0.05)。治疗前,两组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平比较,差异无统计学意义(P>0.05);治疗后,两组TNF-α、IL-6、hs-CRP水平均低于治疗前,且观察组hs-CRP(4.50±1.25)mg/L、TNF-α(13.80±5.05)ng/L、IL-6(12.58±1.10)ng/L均低于对照组的(8.33±2.20)mg/L、(17.70±5.30)ng/L、(15.05±2.20)ng/L,差异有统计学意义(P<0.05)。观察组不良反应发生率为10.71%(6/56),对照组不良反应发生率为8.93%(5/56),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论针对小儿支原体肺炎,与单纯阿奇霉素序贯治疗相比,阿奇霉素序贯联合双黄连口服液治疗的效果更优,其可促进患儿炎症水平改善,且具有安全性理想。

Objective To evaluate the clinical effect of azithromycin sequential therapy combined with Shuanghuanglian oral liquid in the treatment of mycoplasma pneumonia in children.Methods A total of 112 children with mycoplasma pneumonia were divided into the control group and the observation group according to the random numerical table,each with 56 cases.The control group was treated with azithromycin sequential therapy,and the observation group was treated with azithromycin sequential therapy and Shuanghuanglian oral liquid.The therapeutic effects,occurrence of adverse reactions,and inflammatory factors before and after treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.43%,which was significantly higher than 64.29%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and high-sensitivity C-reactive protein(hs-CRP)between the two groups(P>0.05).After treatment,TNF-α,IL-6,and hs-CRP in the two groups were lower than those before treatment;hs-CRP(4.50±1.25)mg/L,TNF-α(13.80±5.05)ng/L,IL-6(12.58±1.10)ng/L of the observation group were lower than(8.33±2.20)mg/L,(17.70±5.30)ng/L,(15.05±2.20)ng/L of the control group;all the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 10.71%(6/56),which was 8.93%(5/56)in the control group,and the difference was not statistically significant(P>0.05).Conclusion Compared with azithromycin sequential therapy alone,the combination of azithromycin sequential therapy and Shuanghuanglian oral liquid has better effect in the treatment of mycoplasma pneumonia in children,and it can improve the level of inflammation in patients with ideal safety.